Literature DB >> 24873919

Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor.

Julien Joskin1, Thierry de Baere, Anne Auperin, Lambros Tselikas, Boris Guiu, Geoffroy Farouil, Valérie Boige, David Malka, Sophie Leboulleux, Michel Ducreux, Eric Baudin, Frédéric Deschamps.   

Abstract

PURPOSE: To investigate predictive factors for liver necrosis after transcatheter arterial chemoembolization (TACE) of neuroendocrine liver metastases.
METHODS: A total of 164 patients receiving 374 TACE were reviewed retrospectively to analyze predictive factors of liver necrosis. We analyzed patient age and sex; metastasis number and location; percentage of liver involvement; baseline liver function test; and pretreatment imaging abnormalities such as bile duct dilatation (BDD), portal vein narrowing (PVN), and portal vein thrombosis (PVT). We analyzed TACE technique such as Lipiodol or drug-eluting beads (DEB) as the drug's vector; dose of chemotherapy; diameter of DEB; and number, frequency, and selectivity of TACE.
RESULTS: Liver necrosis developed after 23 (6.1 %) of 374 TACE. In multivariate analysis, DEB > 300 μm in size induced more liver necrosis compared to Lipiodol (odds ratio [OR] 35.20; p < 0.0001) or with DEB < 300 μm in size (OR 19.95; p < 0.010). Pretreatment BDD (OR 119.64; p < 0.0001) and PVT (OR 9.83; p = 0.030) were predictive of liver necrosis. BDD or PVT responsible for liver necrosis were present before TACE in 59 % (13 of 22) and were induced by a previous TACE in 41 % (9 of 22) of cases.
CONCLUSION: DEB > 300 μm in size, BDD, and PVT are responsible for increased rate of liver necrosis after TACE. Careful analysis of BDD or PVT on pretreatment images as well as images taken between two courses can help avoid TACE complications.

Entities:  

Mesh:

Year:  2014        PMID: 24873919     DOI: 10.1007/s00270-014-0914-1

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

2.  Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.

Authors:  Bruno C Odisio; Aaron Ashton; Yuanqing Yan; Wei Wei; Ahmed Kaseb; Michael J Wallace; Jean N Vauthey; Sanjay Gupta; Alda L Tam
Journal:  J Vasc Interv Radiol       Date:  2015-06-05       Impact factor: 3.464

Review 3.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

4.  Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results.

Authors:  Lawrence Bonne; Chris Verslype; Annouschka Laenen; Sandra Cornelissen; Christophe M Deroose; Hans Prenen; Vincent Vandecaveye; Eric Van Cutsem; Geert Maleux
Journal:  Radiol Oncol       Date:  2017-02-22       Impact factor: 2.991

5.  Portal Vein Damage after DEB-TACE and Lipiodol-TACE: Based on Evaluation by Computed Tomography during Arterial Portography.

Authors:  Masashi Tamura; Seishi Nakatsuka; Hideyuki Torikai; Manabu Misu; Jitsuro Tsukada; Kentaro Tamura; Nobutake Ito; Masanori Inoue; Hideki Yashiro; Masahiro Jinzaki
Journal:  Interv Radiol (Higashimatsuyama)       Date:  2021-11-01

6.  Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma.

Authors:  Cao-Ye Wang; Jin-Guo Xia; Zheng-Qiang Yang; Wei-Zhong Zhou; Wen-Hua Chen; Chun-Jian Qi; Jian-Ping Gu; Qi Wang
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.